Key result
Edoxaban linked to ~33% lower risk of stroke or systemic embolism vs. VKAs.
Why the study?
Observational studies comparing the effectiveness and safety of edoxaban with other oral anticoagulants in patients with AF have yielded disputed results.
Does edoxaban reduce the risk of stroke or systemic embolism and bleeding compared to other oral anticoagulants in patients with non-valvular atrial fibrillation?
Meta-Analysis
Yes
Does edoxaban reduce the risk of stroke or systemic embolism and bleeding compared to other oral anticoagulants in patients with non-valvular atrial fibrillation?
This meta-analysis of observational real-world studies suggests that edoxaban provides superior stroke prevention and a favorable safety profile compared to VKAs and other NOACs.
Answers are grounded in this paper and cite their sources.
Provides low-certainty real-world support for edoxaban over VKAs in AF; leaves open superiority versus other NOACs.
Background and aim: Current observational studies have compared the effectiveness and safety of edoxaban with other oral anticoagulants in patients with AF, but the results are still disputed. This meta-analysis was conducted to compare the effect of edoxaban in patients with AF. Methods: We performed systematic research from the PubMed, EMBASE, and Cochrane Library databases until November 2022 to obtain relevant observational studies. Adjusted risk ratios (RRs) and 95 % confidence intervals (CIs) of the outcomes were collected and pooled by a random-effects model. This study was prospectively registered in PROSPERO (CRD42022314222). Results: A total of 17 observational studies were included in this meta-analysis. Compared with vitamin K antagonists, edoxaban was associated with lower risks of stroke or systemic embolism (RR = 0.67, 95 % CI:0.61-0.74), major bleeding (RR = 0.54, 95 % CI:0.44-0.67), and intracranial hemorrhage (RR = 0.51, 95 % CI:0.29-0.90). Compared with dabigatran or rivaroxaban, edoxaban was associated with reduced risks of stroke or systemic embolism (dabigatran [RR = 0.76, 95 % CI:0.66-0.87]; rivaroxaban [RR = 0.81, 95 % CI:0.70-0.94]) and major bleeding (dabigatran [RR = 0.82, 95 % CI:0.69-0.98]; rivaroxaban [RR = 0.81, 95 % CI:0.70-0.94]). Compared with apixaban, edoxaban was associated with a reduced risk of stroke or systemic embolism (RR = 0.87, 95 % CI:0.79-0.97), but had similar risks of bleeding events. Conclusions: Our current evidence suggested that edoxaban might have superior effectiveness and/or safety outcomes than vitamin K antagonists, dabigatran, rivaroxaban, and apixaban for stroke prevention in patients with AF.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2023) conducted a meta-analysis in Non-valvular atrial fibrillation. Edoxaban vs. Vitamin K antagonists, dabigatran, rivaroxaban, or apixaban was evaluated on Stroke or systemic embolism (compared to vitamin K antagonists) (RR 0.67, 95% CI 0.61-0.74, p=<0.00001). Edoxaban was associated with a 33% reduced risk of stroke or systemic embolism compared to vitamin K antagonists.
Synapse has enriched 10 related papers. Consider them for comparative context: